Disclosure statement
I. Aldoss serves on advisory boards for Amgen, Kite Pharmaceuticals, AbbVie and Agios Pharmaceuticals, Pfizer, and is a consultant for Autolus Therapeutics, Amgen and Pfizer, research support by MacroGenics and Abbvie.
Leukemia & Lymphoma
Volume 63, 2022 - Issue 13
Letters to the Editor
Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis
Idoroenyi Amanama Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USACorrespondence[email protected]
https://orcid.org/0000-0003-4819-4628
https://orcid.org/0000-0003-4819-4628, , Vinod Pullarkata Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USAhttps://orcid.org/0000-0001-9129-3424
https://orcid.org/0000-0001-9129-3424 & Ibrahim Aldossa Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USAhttps://orcid.org/0000-0001-9564-4498
https://orcid.org/0000-0001-9564-4498![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})